The positive-strand RNA virus known as hepatitis C virus (HCV) belongs to the family Flaviviridae's genus Hepacivirus. At least six genotypes (gt) of HCV exist, and the polymerase's error-prone nature results in more than 50 subtypes. The host and viral proteases break down the long open reading frame, which encodes the HCV polyprotein, into seven nonstructural (NS) proteins (p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B) and three structural proteins (the capsid protein core and envelope glycoproteins E1 and E2). While NS3 to NS5B are involved in a membrane-associated RNA replicase complex (RC), NS2 and p7 are required for virus assembly but not RNA replication.NS4A acts as a cofactor for the NS3 serine protease, NS5B is the RNA-dependent RNA polymerase, and NS5A is thought to play important roles in numerous stages of the HCV life cycle. The NS3 protein is made up of a serine protease and an RNA helicase/nucleoside triphosphatase (NTPase).After being administered to HCV-infected cells, NS5A inhibitors quickly reduce the virus' ability to infect cells.
By preventing Kv2.1 function and preventing apoptosis, the HCV protein NS5A prevents the loss of intracellular potassium that would otherwise occur in hepatocytes.
Alpha interferon, Telaprevir, the NS5A inhibitor BMS-790052, and PSI-7977, as well as the combination of lucidone and alpha interferon, all work synergistically to inhibit HCV RNA replication.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V76492 | Sofosbuvir impurity L (sofosbuvir impurity L) | Sofosbuvir impurity L is a diastereoisomer of Sofosbuvir and is an impurity of Sofosbuvir. | |
|
V79741 | Sofosbuvir-13C,d3 (PSI-7977-13C,d3; GS-7977-13C,d3) | Sofosbuvir-13C,d3 is the deuterated form of Sofosbuvir (PSI-7977). | |
|
V54214 | Sofosbuvir-d6 (Sofosbuvir D6; PSI-7977-d6; GS-7977-d6) | 1868135-06-1 | Sofosbuvir-d6 is the deuterium labelled form of Sofosbuvir (PSI-7977). |
|
V54225 | Tetrazolast | 95104-27-1 | Tetrazolast is an HCV (hepatitis C virus) inhibitor (antagonist) with an inhibitory activity between 5% and 20%. |
|
V76408 | TMC647055 Choline salt | TMC647055 (Choline salt) is a potent non-nucleoside NS5B polymerase inhibitor of HCV (hepatitis C virus) replication. | |
|
V76308 | Tobevibart (Tobevibart) | 2645440-65-7 | Tobevibart is an IgG1-lambda humanized monoclonal antibody (mAb) against the surface envelope protein of HBV (hepatitis B virus) (hepatitis B virus). |
|
V37314 | Triton X-45(n=4) | 2315-63-1 | Triton X-45 (n=4) is a nonionic surfactant with a low hydrophilic-lipophilic balance (HLB) value that can be dispersed in aqueous solutions at room temperature and has a Krafft point higher than room temperature. |
|
V3158 | Velpatasvir | 1377049-84-7 | Velpatasvir (formerly known as GS5816; GS-5816;VEL; trade name Vosevi) is apotent, selective, second-generation Hepatitis C virus NS5A protease inhibitor approved for clinical use with sofosbuvir in the treatment of hepatitis C infection of all six major genotypes. |
|
V50981 | WAY-311614 | 297159-02-5 | HCV inhibitor |
|
V51009 | WYE-176115 | 73486-45-0 | NS5B inhibitor |
|
V54216 | Yimitasvir (Emitasvir; DAG-181) | 1959593-23-7 | Yimitasvir (Emitasvir) is an orally bioactive inhibitor of HCV (hepatitis C virus) nonstructural protein 5A (NS5A) and may be utilized in the study of chronic hepatitis C virus infection. |
|
V54215 | Yimitasvir diphosphate (Emitasvir diphosphate; DAG-181 diphosphate) | 1959593-63-5 | Yimitasvir (Emitasvir) diphosphate is an orally bioactive HCV (hepatitis C virus) non-structural protein 5A (NS5A) inhibitor for the study of chronic hepatitis C virus infection. |
|
V76310 | γ-Fagarine | 524-15-2 | γ-Fagarine is a furoquinoline alkaloid naturally occurring in Rutae Herba and has strong anti-HCV (hepatitis C virus) activity with IC50 of 20.4 μg/mL. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
